(lp0
(dp1
S'contVal'
p2
NsS'drug2'
p3
S'http://bio2rdf.org/drugbank:DB00604'
p4
sS'drug1'
p5
S'http://bio2rdf.org/drugbank:DB08567'
p6
sS'objectUri'
p7
NsS'evidence'
p8
NsS'ddiPkMechanism'
p9
NsS'whoAnnotated'
p10
S'consensus set annotator team'
p11
sS'contraindication'
p12
NsS'researchStatementLabel'
p13
NsS'severity'
p14
NsS'label'
p15
NsS'effectConcept'
p16
NsS'source'
p17
S'PK-Corpus'
p18
sS'ddiPkEffect'
p19
NsS'homepage'
p20
NsS'pathway'
p21
NsS'ddiType'
p22
NsS'researchStatement'
p23
NsS'dateAnnotated'
p24
NsS'object'
p25
S'\xef\xbb\xbf(1S,4S)-4-(3,4-DICHLOROPHENYL)-N-METHYL-1,2,3,4-TETRAHYDRONAPHTHALEN-1-AMINE'
p26
sS'evidenceSource'
p27
NsS'evidenceStatement'
p28
S'induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35% | \r'
p29
sS'precipUri'
p30
NsS'certainty'
p31
NsS'uri'
p32
NsS'evidenceType'
p33
NsS'numericVal'
p34
NsS'precaution'
p35
NsS'precipitant'
p36
S'Cisapride'
p37
sa(dp38
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p39
sg5
S'http://bio2rdf.org/drugbank:DB08567'
p40
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p41
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'(1S,4S)-4-(3,4-DICHLOROPHENYL)-N-METHYL-1,2,3,4-TETRAHYDRONAPHTHALEN-1-AMINE'
p42
sg27
Nsg28
S'32% decrease relative to baseline in diazepam clearance | \r'
p43
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p44
sa(dp45
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01100'
p46
sg5
S'http://bio2rdf.org/drugbank:DB08567'
p47
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p48
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'(1S,4S)-4-(3,4-DICHLOROPHENYL)-N-METHYL-1,2,3,4-TETRAHYDRONAPHTHALEN-1-AMINE'
p49
sg27
Nsg28
S'increase in pimozide AUC and C max of about 40% | \r'
p50
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Pimozide'
p51
sa(dp52
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p53
sg5
S'http://bio2rdf.org/drugbank:DB08567'
p54
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p55
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'(1S,4S)-4-(3,4-DICHLOROPHENYL)-N-METHYL-1,2,3,4-TETRAHYDRONAPHTHALEN-1-AMINE'
p56
sg27
Nsg28
S'16% decrease from baseline in the clearance | \r'
p57
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p58
sa(dp59
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00454'
p60
sg5
S'http://bio2rdf.org/drugbank:DB00787'
p61
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p62
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ACICLOVIR'
p63
sg27
Nsg28
S'Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased | \r'
p64
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PETHIDINE'
p65
sa(dp66
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p67
sg5
S'http://bio2rdf.org/drugbank:DB01258'
p68
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p69
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Aliskiren'
p70
sg27
Nsg28
S'AUC and Cmax of furosemide were reduced by about 30% and 50 | \r'
p71
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Furosemide'
p72
sa(dp73
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00993'
p74
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p75
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p76
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Allopurinol'
p77
sg27
Nsg28
S'a reduction in dose to approximately one-third to one-fourth of the usual dose | \r'
p78
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Azathioprine'
p79
sa(dp80
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01151'
p81
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p82
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p83
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Alprazolam'
p84
sg27
Nsg28
S'increased an average of 31% and 20% | \r'
p85
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Desipramine'
p86
sa(dp87
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00458'
p88
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p89
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p90
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Alprazolam'
p91
sg27
Nsg28
S'increased an average of 31% and 20% | \r'
p92
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Imipramine'
p93
sa(dp94
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p95
sg5
S'http://bio2rdf.org/drugbank:DB01370'
p96
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p97
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Aluminium'
p98
sg27
Nsg28
S'been reported to lower serum digoxin levels | \r'
p99
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Digoxin'
p100
sa(dp101
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00489'
p102
sg5
S'http://bio2rdf.org/drugbank:DB01370'
p103
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p104
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Aluminium'
p105
sg27
Nsg28
S'reduction in Cmax and AUC of 26% and 20% | \r'
p106
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sotalol'
p107
sa(dp108
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p109
sg5
S'http://bio2rdf.org/drugbank:DB01072'
p110
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p111
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Atazanavir'
p112
sg27
Nsg28
S'there was a 2-fold increase in the diltiazem plasma concentration and an additive effect on the PR interval | \r'
p113
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Diltiazem'
p114
sa(dp115
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01229'
p116
sg5
S'http://bio2rdf.org/drugbank:DB01072'
p117
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p118
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Atazanavir'
p119
sg27
Nsg28
S'Caution should be used | \r'
p120
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Paclitaxel'
p121
sa(dp122
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00912'
p123
sg5
S'http://bio2rdf.org/drugbank:DB01072'
p124
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p125
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Atazanavir'
p126
sg27
Nsg28
S'Caution should be used | \r'
p127
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Repaglinide'
p128
sa(dp129
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p130
sg5
S'http://bio2rdf.org/drugbank:DB00289'
p131
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p132
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Atomoxetine'
p133
sg27
Nsg28
S'15% increase in AUC | \r'
p134
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p135
sa(dp136
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p137
sg5
S'http://bio2rdf.org/drugbank:DB01076'
p138
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p139
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Atorvastatin'
p140
sg27
Nsg28
S'concentrations increased by approximately 20% | \r'
p141
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Digoxin'
p142
sa(dp143
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00717'
p144
sg5
S'http://bio2rdf.org/drugbank:DB01076'
p145
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p146
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Atorvastatin'
p147
sg27
Nsg28
S'increased AUC | \r'
p148
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Norethindrone'
p149
sa(dp150
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p151
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p152
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p153
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Carbamazepine'
p154
sg27
Nsg28
S'increase alprazolam metabolism | \r'
p155
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alprazolam'
p156
sa(dp157
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p158
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p159
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p160
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Carbamazepine'
p161
sg27
Nsg28
S'causes an approximate 50% increase in the clearance | 40% decrease in the steady-state trough concentrations | \r'
p162
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Felbamate'
p163
sa(dp164
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p165
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p166
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p167
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Carbamazepine'
p168
sg27
Nsg28
S'results in insufficient plasma concentrations | \r'
p169
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nefazodone'
p170
sa(dp171
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01267'
p172
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p173
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p174
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Carbamazepine'
p175
sg27
Nsg28
S'decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50% | \r'
p176
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Paliperidone'
p177
sa(dp178
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00734'
p179
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p180
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p181
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Carbamazepine'
p182
sg27
Nsg28
S'decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50% | may cause a decrease in the combined plasma concentrations | \r'
p183
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Risperidone'
p184
sa(dp185
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00656'
p186
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p187
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p188
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Carbamazepine'
p189
sg27
Nsg28
S'reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively | \r'
p190
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRAZODONE'
p191
sa(dp192
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB08567'
p193
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p194
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p195
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cimetidine'
p196
sg27
Nsg28
S'increases in sertraline mean AUC (50%), C max (24%) and half-life (26 | \r'
p197
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'(1S,4S)-4-(3,4-DICHLOROPHENYL)-N-METHYL-1,2,3,4-TETRAHYDRONAPHTHALEN-1-AMINE'
p198
sa(dp199
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p200
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p201
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p202
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cimetidine'
p203
sg27
Nsg28
S'increased the maximum plasma concentration of alprazolam by 86%, decreased clearance by 42%, and increased half-life by 16% | \r'
p204
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alprazolam'
p205
sa(dp206
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p207
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p208
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p209
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cimetidine'
p210
sg27
Nsg28
S'influence the pharmacokinetics | \r'
p211
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p212
sa(dp213
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p214
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p215
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p216
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cimetidine'
p217
sg27
Nsg28
S'decrease in fluconazole AUC of 13% ? 11% (range: -3.4 to -31%) and Cmax decreased 19% ? 14% (range: -5 to -40% | \r'
p218
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fluconazole'
p219
sa(dp220
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01115'
p221
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p222
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p223
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cimetidine'
p224
sg27
Nsg28
S'AUC values of nifedipine in the presence of cimetidine were between 1.52 and 2.01 times those in the absence | Cmax values of nifedipine in the presence of cimetidine were increased by factors ranging between 1.60 and 2.02 | \r'
p225
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nifedipine'
p226
sa(dp227
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00454'
p228
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p229
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p230
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cimetidine'
p231
sg27
Nsg28
S'reduced the clearance and volume of distribution | \r'
p232
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PETHIDINE'
p233
sa(dp234
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00734'
p235
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p236
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p237
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cimetidine'
p238
sg27
Nsg28
S'increased the bioavailability of risperidone by 64% and 26 | \r'
p239
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Risperidone'
p240
sa(dp241
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01104'
p242
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p243
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p244
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cimetidine'
p245
sg27
Nsg28
S'increases in sertraline mean AUC (50%), C max (24%) and half-life (26 | \r'
p246
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SERTRALINE'
p247
sa(dp248
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00203'
p249
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p250
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p251
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cimetidine'
p252
sg27
Nsg28
S'caused a 56% increase in plasma sildenafil concentrations | \r'
p253
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sildenafil'
p254
sa(dp255
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00382'
p256
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p257
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p258
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cimetidine'
p259
sg27
Nsg28
S'increased the Cmax and AUC of tacrine by approximately 54% and 64% | \r'
p260
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TACRINE'
p261
sa(dp262
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p263
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p264
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p265
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cimetidine'
p266
sg27
Nsg28
S'clearance of verapamil was either reduced or unchanged | \r'
p267
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p268
sa(dp269
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p270
sg5
S'http://bio2rdf.org/drugbank:DB01211'
p271
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p272
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Clarithromycin'
p273
sg27
Nsg28
S'AUC was significantly increased | \r'
p274
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atorvastatin'
p275
sa(dp276
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00734'
p277
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p278
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p279
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLOZAPINE'
p280
sg27
Nsg28
S'may decrease the clearance | \r'
p281
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Risperidone'
p282
sa(dp283
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p284
sg5
S'http://bio2rdf.org/drugbank:DB00872'
p285
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p286
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Conivaptan'
p287
sg27
Nsg28
S'a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC | \r'
p288
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Digoxin'
p289
sa(dp290
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p291
sg5
S'http://bio2rdf.org/drugbank:DB00872'
p292
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p293
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Conivaptan'
p294
sg27
Nsg28
S'increased the mean AUC values by approximately 2- and 3-fold | \r'
p295
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p296
sa(dp297
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00641'
p298
sg5
S'http://bio2rdf.org/drugbank:DB00872'
p299
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p300
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Conivaptan'
p301
sg27
Nsg28
S'resulted in a 3-fold increase in the AUC of simvastatin | \r'
p302
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Simvastatin'
p303
sa(dp304
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p305
sg5
S'http://bio2rdf.org/drugbank:DB00531'
p306
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p307
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cyclophosphamide'
p308
sg27
Nsg28
S'absorption of verapamil can be reduced | \r'
p309
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p310
sa(dp311
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01115'
p312
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p313
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p314
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Diltiazem'
p315
sg27
Nsg28
S'Cmax values of nifedipine increased by factors of 2.0 and 1.7 | \r'
p316
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nifedipine'
p317
sa(dp318
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p319
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p320
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p321
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Diltiazem'
p322
sg27
Nsg28
S'decreases the clearance and increases the t1/2 of quinidine | \r'
p323
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Quinidine'
p324
sa(dp325
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p326
sg5
S'http://bio2rdf.org/drugbank:DB00997'
p327
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p328
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Doxorubicin'
p329
sg27
Nsg28
S'absorption of verapamil can be reduced | absorption of verapamil can be reduced | \r'
p330
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p331
sa(dp332
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p333
sg5
S'http://bio2rdf.org/drugbank:DB00997'
p334
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p335
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Doxorubicin'
p336
sg27
Nsg28
S'absorption of verapamil can be reduced | absorption of verapamil can be reduced | \r'
p337
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p338
sa(dp339
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p340
sg5
S'http://bio2rdf.org/drugbank:DB00625'
p341
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p342
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Efavirenz'
p343
sg27
Nsg28
S'can lead to variable reductions in plasma concentrations | \r'
p344
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atorvastatin'
p345
sa(dp346
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00203'
p347
sg5
S'http://bio2rdf.org/drugbank:DB01240'
p348
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p349
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Epoprostenol'
p350
sg27
Nsg28
S'22% lower mean average steady state concentrations | \r'
p351
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sildenafil'
p352
sa(dp353
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p354
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p355
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p356
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Erythromycin'
p357
sg27
Nsg28
S'increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold | ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold | \r'
p358
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alprazolam'
p359
sa(dp360
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00203'
p361
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p362
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p363
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Erythromycin'
p364
sg27
Nsg28
S'182% increase in sildenafil systemic exposure (AUC | \r'
p365
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sildenafil'
p366
sa(dp367
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p368
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p369
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p370
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Erythromycin'
p371
sg27
Nsg28
S'causing elevation of plasma levels | \r'
p372
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p373
sa(dp374
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p375
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p376
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p377
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Felbamate'
p378
sg27
Nsg28
S'Cmin decreased 31% | decrease in the steady-state carbamazepine plasma concentrations | \r'
p379
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Carbamazepine'
p380
sa(dp381
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB06730'
p382
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p383
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p384
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Felbamate'
p385
sg27
Nsg28
S'42% decrease in the gestodene AUC 0-24 | \r'
p386
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Gestodene'
p387
sa(dp388
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p389
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p390
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p391
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Felbamate'
p392
sg27
Nsg28
S'Cmin concentration increased to 17.8 micrograms/mL | \r'
p393
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p394
sa(dp395
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p396
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p397
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p398
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Felbamate'
p399
sg27
Nsg28
S'increased the steady-state phenytoin Cmin to 25?7 micrograms/mL | increased the steady-state phenytoin Cmin to 25?7 micrograms/mL | \r'
p400
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Phenytoin'
p401
sa(dp402
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p403
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p404
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p405
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Felbamate'
p406
sg27
Nsg28
S'increased the steady-state valproate Cmin to 96?25 micrograms/mL | increase in steady-state valproate concentrations | \r'
p407
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Valproic Acid'
p408
sa(dp409
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p410
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p411
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p412
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Felbamate'
p413
sg27
Nsg28
S'Cmin decreased 31% | decrease in the steady-state carbamazepine plasma concentrations | \r'
p414
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Carbamazepine'
p415
sa(dp416
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p417
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p418
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p419
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Felbamate'
p420
sg27
Nsg28
S'increased the steady-state phenytoin Cmin to 25?7 micrograms/mL | increased the steady-state phenytoin Cmin to 25?7 micrograms/mL | \r'
p421
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Phenytoin'
p422
sa(dp423
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p424
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p425
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p426
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Felbamate'
p427
sg27
Nsg28
S'increased the steady-state valproate Cmin to 96?25 micrograms/mL | increase in steady-state valproate concentrations | \r'
p428
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Valproic Acid'
p429
sa(dp430
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01067'
p431
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p432
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p433
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fluconazole'
p434
sg27
Nsg28
S'percentage increase in the glipizide AUC after fluconazole administration was 56.9% | The AUC and Cmax of glipizide (2.5 mg single dose) were significantly increased | \r'
p435
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Glipizide'
p436
sa(dp437
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p438
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p439
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p440
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fluconazole'
p441
sg27
Nsg28
S'The AUC and Cmax of glyburide (5 mg single dose) were significantly increased | \r'
p442
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Glyburide'
p443
sa(dp444
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p445
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p446
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p447
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fluconazole'
p448
sg27
Nsg28
S'reduced the clearance of IV midazolam by 51% | increased the midazolam AUC and Cmax by 259% and 74% | increased the midazolam AUC and Cmax by 259% and 150% | \r'
p449
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p450
sa(dp451
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00717'
p452
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p453
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p454
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fluconazole'
p455
sg27
Nsg28
S'resulted in small increases in the mean AUCs | \r'
p456
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORETHINDRONE'
p457
sa(dp458
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p459
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p460
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p461
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fluconazole'
p462
sg27
Nsg28
S'increase in phenytoin AUC was 88% | \r'
p463
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Phenytoin'
p464
sa(dp465
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p466
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p467
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p468
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fluconazole'
p469
sg27
Nsg28
S'increase in tolbutamide AUC of 26% | Tolbutamide Cmax increased 11% | \r'
p470
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p471
sa(dp472
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00495'
p473
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p474
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p475
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fluconazole'
p476
sg27
Nsg28
S'significant increase in zidovudine AUC | \r'
p477
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZIDOVUDINE'
p478
sa(dp479
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p480
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p481
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p482
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fluvoxamine'
p483
sg27
Nsg28
S'increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold | ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold | doubled the maximum plasma concentration of alprazolam, decreased clearance by 49%, increased half-life by 71 | \r'
p484
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alprazolam'
p485
sa(dp486
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00321'
p487
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p488
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p489
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fluvoxamine'
p490
sg27
Nsg28
S'Significantly increased plasma TCA levels have been reported | \r'
p491
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Amitriptyline'
p492
sa(dp493
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p494
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p495
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p496
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fluvoxamine'
p497
sg27
Nsg28
S'Elevated carbamazepine levels | \r'
p498
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Carbamazepine'
p499
sa(dp500
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01242'
p501
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p502
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p503
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fluvoxamine'
p504
sg27
Nsg28
S'Significantly increased plasma TCA levels have been reported | Significantly increased plasma TCA levels | \r'
p505
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Clomipramine'
p506
sa(dp507
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p508
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p509
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p510
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fluvoxamine'
p511
sg27
Nsg28
S'influence the pharmacokinetics | \r'
p512
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p513
sa(dp514
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00458'
p515
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p516
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p517
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fluvoxamine'
p518
sg27
Nsg28
S'Significantly increased plasma TCA levels have been reported | \r'
p519
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IMIPRAMINE'
p520
sa(dp521
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00382'
p522
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p523
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p524
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fluvoxamine'
p525
sg27
Nsg28
S'five- and eight-fold increases in tacrine Cmax and AUC | \r'
p526
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TACRINE'
p527
sa(dp528
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00454'
p529
sg5
S'http://bio2rdf.org/drugbank:DB05347'
p530
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p531
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'iontophoretic acyclovir'
p532
sg27
Nsg28
S'Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased | \r'
p533
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PETHIDINE'
p534
sa(dp535
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01258'
p536
sg5
S'http://bio2rdf.org/drugbank:DB01029'
p537
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p538
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Irbesartan'
p539
sg27
Nsg28
S'reduced aliskiren Cmax up to 50 | \r'
p540
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aliskiren'
p541
sa(dp542
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p543
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p544
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p545
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ISONIAZID'
p546
sg27
Nsg28
S'increase its serum levels | \r'
p547
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Carbamazepine'
p548
sa(dp549
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01258'
p550
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p551
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p552
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p553
sg27
Nsg28
S'80% increase in plasma levels of aliskiren | \r'
p554
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aliskiren'
p555
sa(dp556
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p557
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p558
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p559
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p560
sg27
Nsg28
S'increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold | ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold | \r'
p561
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alprazolam'
p562
sa(dp563
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00872'
p564
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p565
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p566
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p567
sg27
Nsg28
S'resulted in 4- and 11-fold increases in Cmax and AUC | \r'
p568
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Conivaptan'
p569
sa(dp570
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB06700'
p571
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p572
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p573
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p574
sg27
Nsg28
S'Cmax increased by 26% in EM subjects and 48% in PM subjects | resulted in higher plasma concentrations | AUC increased by 21% in EM subjects and 70% in PM subjects | \r'
p575
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Desvenlafaxine'
p576
sa(dp577
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p578
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p579
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p580
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p581
sg27
Nsg28
S'influence the pharmacokinetics | \r'
p582
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Diazepam'
p583
sa(dp584
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p585
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p586
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p587
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p588
sg27
Nsg28
S'quinidine levels rise when ketoconazole is coadministered | \r'
p589
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Quinidine'
p590
sa(dp591
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p592
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p593
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p594
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Lansoprazole'
p595
sg27
Nsg28
S'may interfere with the absorption | \r'
p596
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPICILLIN'
p597
sa(dp598
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p599
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p600
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p601
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Lansoprazole'
p602
sg27
Nsg28
S'decrease the systemic concentrations | \r'
p603
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atazanavir'
p604
sa(dp605
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p606
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p607
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p608
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Lansoprazole'
p609
sg27
Nsg28
S'may interfere with the absorption | \r'
p610
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Digoxin'
p611
sa(dp612
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01592'
p613
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p614
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p615
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Lansoprazole'
p616
sg27
Nsg28
S'may interfere with the absorption | \r'
p617
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Iron'
p618
sa(dp619
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p620
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p621
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p622
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Lansoprazole'
p623
sg27
Nsg28
S'may interfere with the absorption | \r'
p624
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p625
sa(dp626
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p627
sg5
S'http://bio2rdf.org/drugbank:DB01601'
p628
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p629
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Lopinavir'
p630
sg27
Nsg28
S'AUC was significantly increased | \r'
p631
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atorvastatin'
p632
sa(dp633
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p634
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p635
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p636
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p637
sg27
Nsg28
S'the rate and/or extent of absorption of drugs from the small bowel may be increased | \r'
p638
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Acetaminophen'
p639
sa(dp640
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p641
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p642
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p643
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p644
sg27
Nsg28
S'Absorption of drugs from the stomach may be diminished | \r'
p645
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Digoxin'
p646
sa(dp647
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p648
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p649
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p650
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p651
sg27
Nsg28
S'the rate and/or extent of absorption of drugs from the small bowel may be increased | \r'
p652
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ethanol'
p653
sa(dp654
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01235'
p655
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p656
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p657
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p658
sg27
Nsg28
S'the rate and/or extent of absorption of drugs from the small bowel may be increased | \r'
p659
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'L-DOPA'
p660
sa(dp661
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00759'
p662
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p663
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p664
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p665
sg27
Nsg28
S'the rate and/or extent of absorption of drugs from the small bowel may be increased | \r'
p666
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tetracycline'
p667
sa(dp668
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p669
sg5
S'http://bio2rdf.org/drugbank:DB01149'
p670
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p671
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Nefazodone'
p672
sg27
Nsg28
S'ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold | peak concentrations, AUC and half-life values for alprazolam increased by approximately 2-fold | increased alprazolam concentration two-fold | increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold | \r'
p673
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alprazolam'
p674
sa(dp675
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p676
sg5
S'http://bio2rdf.org/drugbank:DB01149'
p677
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p678
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Nefazodone'
p679
sg27
Nsg28
S'half-life and AUC increased 4-fold and peak concentrations increased 1.7-fold | \r'
p680
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Triazolam'
p681
sa(dp682
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00289'
p683
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p684
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p685
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Paroxetine'
p686
sg27
Nsg28
S'cause similar increases in exposure | the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater | atomoxetine Cmax values that were 3- to 4-fold greater | increase in atomoxetine plasma exposure | increase atomoxetine steady-state plasma concentrations | increases in steady state atomoxetine AUC values that were 6- to 8-fold greater | \r'
p687
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atomoxetine'
p688
sa(dp689
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01151'
p690
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p691
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p692
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PAROXETINE'
p693
sg27
Nsg28
S'increased single-dose desipramine (100 mg) Cmax, AUC, and T? by an average of approximately 2-, 5-, and 3-fold | \r'
p694
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Desipramine'
p695
sa(dp696
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01267'
p697
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p698
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p699
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PAROXETINE'
p700
sg27
Nsg28
S'decreased 9-hydroxyrisperidone concentrations approximately 10% | lowered the concentration of 9-hydroxyrisperidone by about 10% | \r'
p701
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Paliperidone'
p702
sa(dp703
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p704
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p705
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p706
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PAROXETINE'
p707
sg27
Nsg28
S'AUC was slightly reduced (12% on average) | \r'
p708
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Phenytoin'
p709
sa(dp710
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01100'
p711
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p712
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p713
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PAROXETINE'
p714
sg27
Nsg28
S'increases in pimozide AUC of 151% and Cmax of 62% | \r'
p715
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Pimozide'
p716
sa(dp717
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00734'
p718
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p719
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p720
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PAROXETINE'
p721
sg27
Nsg28
S'increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold | increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold | increased mean plasma concentrations of risperidone approximately 4-fold | \r'
p722
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Risperidone'
p723
sa(dp724
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p725
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p726
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p727
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p728
sg27
Nsg28
S'AUC and T? were reduced (by an average of 25% and 38% | \r'
p729
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Paroxetine'
p730
sa(dp731
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00734'
p732
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p733
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p734
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p735
sg27
Nsg28
S'may cause a decrease in the combined plasma concentrations | may cause similar decreases in the combined plasma concentrations | \r'
p736
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Risperidone'
p737
sa(dp738
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p739
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p740
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p741
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p742
sg27
Nsg28
S'may increase verapamil clearance | \r'
p743
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p744
sa(dp745
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p746
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p747
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p748
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Phenytoin'
p749
sg27
Nsg28
S'causes an approximate doubling of the clearance | 45% decrease in the steady-state trough concentrations | \r'
p750
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Felbamate'
p751
sa(dp752
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p753
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p754
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p755
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Phenytoin'
p756
sg27
Nsg28
S'causes an approximate doubling of the clearance | 45% decrease in the steady-state trough concentrations | \r'
p757
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Felbamate'
p758
sa(dp759
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p760
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p761
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p762
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Phenytoin'
p763
sg27
Nsg28
S'A clinically significant fluvoxamine interaction | \r'
p764
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fluvoxamine'
p765
sa(dp766
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01115'
p767
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p768
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p769
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Phenytoin'
p770
sg27
Nsg28
S'lowered the AUC and Cmax of nifedipine by approximately 70% | \r'
p771
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nifedipine'
p772
sa(dp773
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p774
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p775
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p776
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Phenytoin'
p777
sg27
Nsg28
S'AUC and T? were reduced (by an average of 50% and 35% | \r'
p778
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAROXETINE'
p779
sa(dp780
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00734'
p781
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p782
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p783
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Phenytoin'
p784
sg27
Nsg28
S'may cause a decrease in the combined plasma concentrations | may cause similar decreases in the combined plasma concentrations | \r'
p785
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Risperidone'
p786
sa(dp787
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00495'
p788
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p789
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p790
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Phenytoin'
p791
sg27
Nsg28
S'30% decrease in oral zidovudine clearance was observed | \r'
p792
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZIDOVUDINE'
p793
sa(dp794
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p795
sg5
S'http://bio2rdf.org/drugbank:DB01100'
p796
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p797
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Pimozide'
p798
sg27
Nsg28
S'A clinically significant fluvoxamine interaction | \r'
p799
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fluvoxamine'
p800
sa(dp801
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p802
sg5
S'http://bio2rdf.org/drugbank:DB00635'
p803
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p804
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Prednisone'
p805
sg27
Nsg28
S'absorption of verapamil can be reduced | \r'
p806
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p807
sa(dp808
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p809
sg5
S'http://bio2rdf.org/drugbank:DB01168'
p810
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p811
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Procarbazine'
p812
sg27
Nsg28
S'absorption of verapamil can be reduced | \r'
p813
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p814
sa(dp815
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00289'
p816
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p817
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p818
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Quinidine'
p819
sg27
Nsg28
S'increase atomoxetine steady-state plasma concentrations | results in a substantial increase in atomoxetine plasma exposure | increase in atomoxetine plasma exposure | cause similar increases in exposure | \r'
p820
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atomoxetine'
p821
sa(dp822
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01115'
p823
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p824
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p825
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Quinidine'
p826
sg27
Nsg28
S'increased Cmax and AUC of nifedipine in healthy volunteers by factors of 2.30 and 1.37 | \r'
p827
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nifedipine'
p828
sa(dp829
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p830
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p831
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p832
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Rifampicin'
p833
sg27
Nsg28
S'can lead to variable reductions in plasma concentrations | \r'
p834
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atorvastatin'
p835
sa(dp836
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00612'
p837
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p838
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p839
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Rifampicin'
p840
sg27
Nsg28
S'increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life | \r'
p841
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Bisoprolol'
p842
sa(dp843
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p844
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p845
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p846
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Rifampicin'
p847
sg27
Nsg28
S'half-life decreased from 33.4 ? 4.4 hours to 26.8 ? 3.9 hours | significant decrease in fluconazole AUC | \r'
p848
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fluconazole'
p849
sa(dp850
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00497'
p851
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p852
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p853
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Rifampicin'
p854
sg27
Nsg28
S'decreased plasma oxycodone concentrations | decreased oxycodone AUC and Cmax values by 86% and 63% | \r'
p855
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Oxycodone'
p856
sa(dp857
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00734'
p858
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p859
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p860
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Rifampicin'
p861
sg27
Nsg28
S'may cause similar decreases in the combined plasma concentrations | may cause a decrease in the combined plasma concentrations | \r'
p862
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Risperidone'
p863
sa(dp864
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p865
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p866
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p867
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Rifampicin'
p868
sg27
Nsg28
S'lowering of plasma levels | reduce oral verapamil bioavailability | \r'
p869
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p870
sa(dp871
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p872
sg5
S'http://bio2rdf.org/drugbank:DB00734'
p873
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p874
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Risperidone'
p875
sg27
Nsg28
S'there was a 20% increase in valproate peak plasma concentration (Cmax | \r'
p876
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Valproic Acid'
p877
sa(dp878
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p879
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p880
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p881
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ritonavir'
p882
sg27
Nsg28
S'AUC was significantly increased | \r'
p883
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atorvastatin'
p884
sa(dp885
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00203'
p886
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p887
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p888
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ritonavir'
p889
sg27
Nsg28
S'1000% (11-fold) increase in sildenafil plasma AUC | resulted in a 300% (4-fold) increase in sildenafil Cmax | \r'
p890
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sildenafil'
p891
sa(dp892
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00656'
p893
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p894
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p895
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ritonavir'
p896
sg27
Nsg28
S'can be inhibited | Cmax of trazodone increased by 34%, the AUC increased 2.4 fold, the half-life increased by 2.2 fold, and the clearance decreased by 52% | \r'
p897
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Trazodone'
p898
sa(dp899
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p900
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p901
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p902
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ritonavir'
p903
sg27
Nsg28
S'causing elevation of plasma levels | \r'
p904
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p905
sa(dp906
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p907
sg5
S'http://bio2rdf.org/drugbank:DB00412'
p908
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p909
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Rosiglitazone'
p910
sg27
Nsg28
S'decrease in glyburide AUC and Cmax of approximately 30% | AUC and Cmax slightly increased | \r'
p911
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Glyburide'
p912
sa(dp913
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p914
sg5
S'http://bio2rdf.org/drugbank:DB01104'
p915
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p916
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SERTRALINE'
p917
sg27
Nsg28
S'induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35% | \r'
p918
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p919
sa(dp920
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p921
sg5
S'http://bio2rdf.org/drugbank:DB01104'
p922
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p923
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SERTRALINE'
p924
sg27
Nsg28
S'32% decrease relative to baseline in diazepam clearance | \r'
p925
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p926
sa(dp927
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01100'
p928
sg5
S'http://bio2rdf.org/drugbank:DB01104'
p929
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p930
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SERTRALINE'
p931
sg27
Nsg28
S'increase in pimozide AUC and C max of about 40% | \r'
p932
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Pimozide'
p933
sa(dp934
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p935
sg5
S'http://bio2rdf.org/drugbank:DB01104'
p936
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p937
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SERTRALINE'
p938
sg27
Nsg28
S'16% decrease from baseline in the clearance | \r'
p939
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p940
sa(dp941
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p942
sg5
S'http://bio2rdf.org/drugbank:DB00641'
p943
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p944
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Simvastatin'
p945
sg27
Nsg28
S'increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL | slight elevation in digoxin concentrations | \r'
p946
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Digoxin'
p947
sa(dp948
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p949
sg5
S'http://bio2rdf.org/drugbank:DB01015'
p950
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p951
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Sulfamethoxazole'
p952
sg27
Nsg28
S'may inhibit the hepatic metabolism | increased the phenytoin half-life by 39% and decreased the phenytoin metabolic clearance rate by 27% | \r'
p953
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Phenytoin'
p954
sa(dp955
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p956
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p957
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p958
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Valproic Acid'
p959
sg27
Nsg28
S'not expected to cause a clinically important effect on Felbatol\xc3\xaf\xc2\xbe\xc2\xab (felbamate) plasma concentrations | \r'
p960
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Felbamate'
p961
sa(dp962
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01258'
p963
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p964
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p965
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Verapamil'
p966
sg27
Nsg28
S'2-fold increase in Cmax and AUC | \r'
p967
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aliskiren'
p968
sa(dp969
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p970
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p971
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p972
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Verapamil'
p973
sg27
Nsg28
S'increase carbamazepine concentrations | \r'
p974
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Carbamazepine'
p975
sa(dp976
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01396'
p977
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p978
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p979
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Verapamil'
p980
sg27
Nsg28
S'reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29 | \r'
p981
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Digitoxin'
p982
sa(dp983
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p984
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p985
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p986
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Verapamil'
p987
sg27
Nsg28
S'increase serum digoxin levels by 50% to 75 | \r'
p988
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Digoxin'
p989
sa(dp990
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00997'
p991
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p992
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p993
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Verapamil'
p994
sg27
Nsg28
S'increase doxorubicin levels | \r'
p995
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Doxorubicin'
p996
sa(dp997
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p998
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p999
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p1000
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Verapamil'
p1001
sg27
Nsg28
S'inhibit ethanol elimination resulting in elevated blood ethanol concentrations | \r'
p1002
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ethanol'
p1003
sa(dp1004
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01229'
p1005
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p1006
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p1007
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Verapamil'
p1008
sg27
Nsg28
S'can decrease the clearance | \r'
p1009
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Paclitaxel'
p1010
sa(dp1011
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p1012
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p1013
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p1014
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Verapamil'
p1015
sg27
Nsg28
S'increased quinidine levels | \r'
p1016
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Quinidine'
p1017
sa(dp1018
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p1019
sg5
S'http://bio2rdf.org/drugbank:DB00541'
p1020
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p1021
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Vincristine'
p1022
sg27
Nsg28
S'absorption of verapamil can be reduced | absorption of verapamil can be reduced | \r'
p1023
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p1024
sa(dp1025
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p1026
sg5
S'http://bio2rdf.org/drugbank:DB00541'
p1027
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p1028
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Vincristine'
p1029
sg27
Nsg28
S'absorption of verapamil can be reduced | absorption of verapamil can be reduced | \r'
p1030
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p1031
sa(dp1032
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00497'
p1033
sg5
S'http://bio2rdf.org/drugbank:DB00582'
p1034
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p1035
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Voriconazole'
p1036
sg27
Nsg28
S'increased oxycodone AUC and Cmax by 3.6 and 1.7 fold | increased the plasma concentrations | \r'
p1037
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Oxycodone'
p1038
sa(dp1039
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p1040
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p1041
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p1042
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Zidovudine'
p1043
sg27
Nsg28
S'substantially decreases the systemic concentrations | \r'
p1044
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atazanavir'
p1045
sa(dp1046
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p1047
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p1048
sg7
Nsg8
Nsg9
Nsg10
S'consensus set annotator team'
p1049
sg12
Nsg13
Nsg14
Nsg15
Nsg16
Nsg17
g18
sg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ZIDOVUDINE'
p1050
sg27
Nsg28
S'plasma levels have been reported to be low | \r'
p1051
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Phenytoin'
p1052
sa.